Abstract
SOLANA (NCT02869438), a 12-week, multinational, randomized, double-blind, placebo-controlled, Phase IIIb onset-of-effect characterization study, was the first benralizumab study for patients with asthma to include the St. George’s Respiratory Questionnaire (SGRQ). The SGRQ is a 50-item health status assessment tool developed for respiratory conditions involving chronic airflow limitation. Total and domain (symptom, activity, and psychosocial impact) scores are weighted and expressed as percentages (0–100), with larger values indicating greater impairment. The objective of this analysis was to evaluate effect onset and maintenance as measured by SGRQ total and domain scores for patients enrolled in SOLANA receiving benralizumab vs. placebo.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
